WebGalectin Therapeutics uses its knowledge of galectin proteins to study the effects of our proprietary compounds in diseases with clinical needs. Our compounds act as galectin inhibitors, binding to galectin proteins and … WebMar 7, 2011 · Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby grants, as of March 7, 2011 (the “Grant,” and such date, the “Grant Date”), to Peter G. Traber, M.D. (the “Optionee”) an option (the “Option”) to purchase up to 5,000,000 shares of the Company’s common stock, $0.001 par value per share (the “Shares ...

Proprietary galectin inhibitors to treat disease

WebThe galectin-3 (gal-3) protein appears to be critical to the process of fibrogenesis, and targeting gal-3 could potentially treat a broad spectrum of diseases. Two approaches have been taken to develop drugs that bind gal-3. One involves modified disaccharides (TD139), and the other uses large polysaccharides that contain galactose (GR-MD-02). WebApr 14, 2024 · The drug pipelines for galectin-targeting modalities is currently in infancy and is dominated by some biotechnology companies that are working on galectin-targeted therapies; however, similar projects at major pharmaceutical companies are either nonexistent or in the early stages and have not yet being announced in the public. outsider wife

TrueBinding

WebApr 10, 2024 · Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. WebJul 24, 2014 · Among these are Galectin Therapeutics Inc. , Intercept Pharmaceuticals , Raptor Pharmaceuticals and Gilead Sciences , all of which are in search of a cure for one stage or another of "fatty liver ... WebGalectins are a class of proteins that bind specifically to β-galactoside sugars, such as N -acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc), which can be bound to proteins … outsider where to watch